) reported second-quarter earnings that beat estimates on both revenue and profit. The company posted revenue of $22.45 billion, surpassing the expected $22.34 billion, while adjusted EPS came in at $2.82, above the projected $2.71. Despite this strong performance, JNJ lowered its full-year guidance, citing impacts from recent acquisitions.
Joining me now for a deeper dive into this report is Joe Johnson and Johnson CFO and Executive Vice President Joe.It's It's been quite a while since we've had the chance to discuss, uh, our business, which I'm certainly proud to do on on the results of the second quarter.Quite frankly, I think investors have seen the strength of Johnson and Johnson the diversity of our portfolio.
Uh, really elevates our presence in cardiovascular, and it's, uh, performing ahead of the model expectations at the time.You may recall, Angelique. And we have plans in place to really improve that business with better health care provider interactions going forward, where some new regulations are impacting volume.On the innovative medicine side, I know you're looking forward to the impact from Stelara.In addition, you also have, um, the different, you know, movement that you have in this sector within with the investment you've made in R and D as well.So a lot of little moving parts there.
Uh, as we shared at our Enterprise Business Review in December, we now have at least 10 products or platforms.So we feel very good about how we've been able to fortify that again.
Россия Последние новости, Россия Последние новости
Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей
Источник: YahooFinanceCA - 🏆 47. / 63 Прочитайте больше »